Clinical Trial Update: Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating elotuzumab for JAK2-mutated myelofibrosis; the study is active but not recruiting and includes myelofibrosis arising from esse…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia
• Myelofibrosis
• Polycythemia Vera
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• Elotuzumab (elotuzumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Phase 2 | Status: ACTIVE_NOT_RECRUITING